Friedhelm Blobel, Ph.D.
President and Chief Executive Officer, Director
Friedhelm Blobel, Ph.D., has served as our President, Chief Executive Officer and a Director since June 2006. Previously, Dr. Blobel was President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a South San Francisco-based biopharmaceutical company. Prior to joining Gryphon Therapeutics in July 2000, Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group, including responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer and General Manager in Tokyo, Japan of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas Pharma, Inc.), Senior Vice President of Research and Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana. Dr. Blobel earned his doctorate degree (“Dr.rer.nat.”; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany.
Chief Executive Officer, China Operations
Hong Zhao joined SciClone as Chief Executive Officer, China Operations, in April 2013. Prior to SciClone, Mr. Zhao served as Executive Vice President of Simcere Pharmaceutical Group, a manufacturer and supplier of pharmaceuticals in China, where he was responsible for all business operations and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training and personnel development. Prior to Simcere, Mr. Zhao held various positions at Novartis China, a health care products company, including most recently, Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai. Mr. Zhao earned a Bachelor of Medicine degree from Nanjing Medical College and an Executive Masters of Business Administration degree from China European International Business School (CEIBS) in Shanghai.
Wilson W. Cheung
Chief Financial Officer, Senior Vice President, Finance and Secretary
Wilson W. Cheung joined SciClone in July 2013 and serves as Chief Financial Officer, Senior Vice President, Finance and Secretary. Prior to joining SciClone, Mr. Cheung served in various positions at Velti plc, a publicly traded global mobile marketing and advertising software-as-a-service provider, including most recently as Chief Compliance Officer, Asia Pacific and previously as Chief Financial Officer. Prior to Velti, Mr. Cheung served as Chief Financial Officer at AXT, Inc., a California-based, publicly traded manufacturer of high performance semiconductor substrates. Mr. Cheung holds a B.A. degree from the University of California, Los Angeles (UCLA), and is a Certified Director of Corporate Governance from UCLA's Executive Program. He is a California Certified Public Accountant (inactive).
Carey Chern joined SciClone in October 2016 and serves as General Counsel. Prior to joining SciClone, from 2011 to 2016, Mr. Chern served as division counsel for the Professional Products Division (healthcare, food, cleaning) and Senior Corporate Counsel at The Clorox Company, a publicly traded consumer (and institutional) products company. From 2006 to 2010, Mr. Chern served as Senior Counsel at Amgen Inc., a publicly traded biotechnology company. From 1997 to 2005, Mr. Chern held various positions of increasing responsibility as an attorney at Heller Ehrman LLP. Mr. Chern earned his J.D. from Stanford Law School and his A.B. from Harvard University.
Robert King, Ph.D.
Senior Vice President, Product Development and Manufacturing
Robert King joined SciClone in 2011, and serves as Senior Vice President, Product Development and Supply Chain. Prior to joining SciClone, Dr. King served as Vice President, Product Development and Manufacturing at Bayhill Therapeutics. Prior to Bayhill, Dr. King was VP, Product Development and Manufacturing at Rinat Neuroscience Corporation (a division of Pfizer Global R & D). Dr. King has a PhD in Chemical Engineering from UC Berkeley and a BS in Chemical Engineering from the University of Washington.
Raymond A. Low
Vice President, Finance and Controller
Raymond A. Low joined SciClone as Vice President, Finance and Controller in October 2013. Prior to joining SciClone, Mr. Low served as Chief Financial Officer, and was previously Corporate Controller, at AXT, Inc., a publicly traded manufacturer of high performance semi-conductor substrates. Formerly, Mr. Low was Corporate Controller of Therasense, Inc. (now Abbott Laboratories), a health care products company. Mr. Low is a California certified public accountant, and a member of the California Society of CPAs. He is a past member of the Chartered Institute of Management Accountants in the United Kingdom. Mr. Low has an M.B.A. degree from Chadwick University, Alabama, a Bachelor of Accounting Science Honors degree from the University of South Africa, and a Bachelor of Commerce degree from Rhodes University, South Africa.
Vice President, Finance and Chief Financial Officer, China Operations
Lan Xie joined SciClone as Vice President, Finance, China Chief Financial Officer in 2012. Ms. Xie served as Vice President of Finance and Investor Relations at Shangpharma Corporation, a pharmaceutical company. Ms. Xie served as a senior manager, transaction services, at PriceWaterhouseCoopers Zhong Tian LLP in Shanghai, and previously served as manager, mergers and acquisitions at Deloitte & Touche in New York. She is a Massachusetts certified public accountant and received her MBA from INSEAD, Singapore/France.